BECOMING THE UNDISPUTED DERMATOLOGY POWERHOUSE
Galderma entered 2025 with strong momentum following our landmark initial public offering on the SIX Swiss Exchange in 2024. Over the year, we accelerated our trajectory advancing the world’s broadest dermatology portfolio—spanning Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology—and further strengthening our foundation for long-term growth.
Delivering on our purpose
We made important strides towards our purpose of advancing dermatology for every skin story in 2025, with achievements that strengthened our foundation and positioned us for continued growth.
2025 MILESTONES
Received regulatory approval for Nemluvio® (nemolizumab) in the EU
for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis, and marketing authorization in the U.K., Switzerland and Singapore for both indications.
Opened our new U.S. and Latin America headquarters in Miami, Florida
positioning Galderma at the heart of a thriving market for Dermatological Skincare and Injectable Aesthetics.
Unveiled nine-month data showing lasting efficacy and patient satisfaction with our Injectable Aesthetics portfolio
when addressing facial aesthetic changes after medication-driven weight loss, and published a ground-breaking report on the topic.
Joined the Swiss Leader Index
as one of the 30 largest and most liquid securities in the Swiss equity market.
Welcomed more than 1,000 healthcare professionals at GAIN LATAM in São Paolo, Brazil
celebrating 10 years of GAIN and 30 years of Galderma in Latin America.
Presented new findings showing the impact of modern living on sensitive skin at EADV 2025
alongside new data on our novel biologic’s mode of action in atopic dermatitis, and its long-term safety and efficacy in prurigo nodularis and moderate-to-severe atopic dermatitis up to two years.
Received U.S. FDA approval of Restylane® Lyft™
for the enhancement of the chin profile
based on results from a pivotal clinical trial.
Enrolled the first patient
in a study assessing nemolizumab in adults with Chronic Pruritus of Unknown Origin.
SCIENCE FUELING GROWTH: leveraging our in-house R&D capabilities
At Galderma, research and development (R&D) is central to how we advance the future of dermatology. By translating scientific progress into meaningful solutions, we strengthen our contribution to improving skin health.
PIPELINE TO PRODUCT: our portfolio spanning the full spectrum of dermatology
Our synergistic, science-backed portfolio drives growth and innovation. Through clinical research, trusted partnerships and execution excellence we continue to strengthen our leadership and expand options across dermatology.
PROGRESS WITH PURPOSE: advancing our ESG strategy
At Galderma, Environmental, Social and Governance (ESG) considerations are a key part of our Integrated Dermatology Strategy. Our commitment begins with our purpose of advancing dermatology for every skin story and extends to how we meet the needs of our consumers and patients.
Learn more abour our ESG
-
• 70+ major health authority approvals
• Two new clinical trials: Systemic Sclerosis and Chronic Pruritus of Unknown Origin
-
• 290,00+ healthcare professionals reached through education, training and medical awareness activities
-
• >40% women in Galderma management
• <0.9 work-related accidents per million working hours
-
• 0 Class I product recalls
• >95% of regulatory and notified body inspections without critical findings
-
• >98% renewable electricity across all our sites
• >15% annual water withdrawal intensity reduction
-
• >40% of affiliates with Great Place to Work® certificates
• >98% completion rate of end-of-year performance review
